Miao94的个人主页 - 老虎社区

Miao94

Miao94

暂无个人介绍

IP属地：未知

16关注

0粉丝

0主题

0勋章

2021-06-21

Great ariticle, would you like to share it?

抱歉，原内容已删除

2021-06-21

Great ariticle, would you like to share it?

30Y Treasury Yield Tumbles Below 2.00%, Japanese Stocks Plunge

2021-06-21

Good

抱歉，原内容已删除

2021-06-21

Great ariticle, would you like to share it?

抱歉，原内容已删除

2021-06-20

[开心]

抱歉，原内容已删除

2021-06-20

Great ariticle, would you like to share it?

PLTR Stock: The Palantir-FAA Deal News Should Have Investors Smiling Today

2021-06-20

Great

抱歉，原内容已删除

2021-06-20

Great ariticle, would you like to share it?

抱歉，原内容已删除

2021-06-19

Great ariticle, would you like to share it?

抱歉，原内容已删除

2021-06-18

Great ariticle, would you like to share it?

Inflation breakout will drive 10-year Treasury yields above 2% in coming months, Wells Fargo predicts

2021-06-18

Nice

抱歉，原内容已删除

2021-06-18

Go go go

抱歉，原内容已删除

2021-06-18

Sad

Low dosage may be behind low efficacy of CureVac vaccine: Study leader

2021-06-18

[微笑]

Column: The FDA's hasty approval of a new Alzheimer's drug is looking worse than ever

2021-06-18

Good

抱歉，原内容已删除

2021-06-18

Great ariticle, would you like to share it?

抱歉，原内容已删除

2021-06-18

Comments

抱歉，原内容已删除

2021-06-18

Great ariticle, would you like to share it?

抱歉，原内容已删除

2021-06-18

Great ariticle, would you like to share it?

抱歉，原内容已删除

2021-06-18

Comment

Downtrodden Okta Stock Still Has a Chance to Shine Again

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3581763489080929","uuid":"3581763489080929","gmtCreate":1618669619634,"gmtModify":1618671418322,"name":"Miao94","pinyin":"miao94","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/34f3df2688773fe9bc20c385589224ea","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":16,"tweetSize":22,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.17","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":167827446,"gmtCreate":1624260901785,"gmtModify":1634008746465,"author":{"id":"3581763489080929","authorId":"3581763489080929","name":"Miao94","avatar":"https://static.tigerbbs.com/34f3df2688773fe9bc20c385589224ea","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581763489080929","authorIdStr":"3581763489080929"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/167827446","repostId":"2144870437","repostType":4,"isVote":1,"tweetType":1,"viewCount":486,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":167827619,"gmtCreate":1624260885531,"gmtModify":1634008746712,"author":{"id":"3581763489080929","authorId":"3581763489080929","name":"Miao94","avatar":"https://static.tigerbbs.com/34f3df2688773fe9bc20c385589224ea","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581763489080929","authorIdStr":"3581763489080929"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/167827619","repostId":"1111222251","repostType":4,"repost":{"id":"1111222251","kind":"news","pubTimestamp":1624259801,"share":"https://www.laohu8.com/m/news/1111222251?lang=&edition=full","pubTime":"2021-06-21 15:16","market":"us","language":"en","title":"30Y Treasury Yield Tumbles Below 2.00%, Japanese Stocks Plunge","url":"https://stock-news.laohu8.com/highlight/detail?id=1111222251","media":"zerohedge","summary":"Short-dated Treasury yields are extending their rise from Friday's bloodbath as the collapse of the ","content":"<p>Short-dated Treasury yields are extending their rise from Friday's bloodbath as the collapse of the long-end of the term structure accelerates in early Asia trading.</p>\n<p>2Y is back above the Fed Funds rate...</p>\n<p><img src=\"https://static.tigerbbs.com/8b00147e9ac51186c9910c1b0226d4a8\" tg-width=\"500\" tg-height=\"273\"><i>Source: Bloomberg</i></p>\n<p>and 30Y yields are back below 2.00%...</p>\n<p><img src=\"https://static.tigerbbs.com/f8f5270edd9cc600dfb21ceba4cf0e77\" tg-width=\"500\" tg-height=\"273\"></p>\n<p>... for the first time since March...</p>\n<p><img src=\"https://static.tigerbbs.com/57cd958ccfbd05605a1803b430baa2ee\" tg-width=\"500\" tg-height=\"273\"><i>Source: Bloomberg</i></p>\n<p>10Y yields are at their lowest since early March...</p>\n<p><img src=\"https://static.tigerbbs.com/63a614b415615f0cb00431f4491227a5\" tg-width=\"500\" tg-height=\"268\"><i>Source: Bloomberg</i></p>\n<p>And Japanese equity markets are none too happy with Powell's policy error malarkey...</p>\n<p><img src=\"https://static.tigerbbs.com/3de5627dd059fff0076ce68b72e2c7c9\" tg-width=\"500\" tg-height=\"271\"><i>Source: Bloomberg</i></p>\n<p>AsLance Roberts noted earlier,<b>there have been ZERO times in history when the Fed started a rate hiking campaign that did not lead to a negative outcome.</b>We suggest this time won’t be any different.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>30Y Treasury Yield Tumbles Below 2.00%, Japanese Stocks Plunge</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n30Y Treasury Yield Tumbles Below 2.00%, Japanese Stocks Plunge\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-21 15:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.zerohedge.com/markets/30y-treasury-yield-tumbles-below-200-japanese-stocks-plunge><strong>zerohedge</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Short-dated Treasury yields are extending their rise from Friday's bloodbath as the collapse of the long-end of the term structure accelerates in early Asia trading.\n2Y is back above the Fed Funds ...</p>\n\n<a href=\"https://www.zerohedge.com/markets/30y-treasury-yield-tumbles-below-200-japanese-stocks-plunge\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯","SPY":"标普500ETF",".SPX":"S&P 500 Index"},"source_url":"https://www.zerohedge.com/markets/30y-treasury-yield-tumbles-below-200-japanese-stocks-plunge","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111222251","content_text":"Short-dated Treasury yields are extending their rise from Friday's bloodbath as the collapse of the long-end of the term structure accelerates in early Asia trading.\n2Y is back above the Fed Funds rate...\nSource: Bloomberg\nand 30Y yields are back below 2.00%...\n\n... for the first time since March...\nSource: Bloomberg\n10Y yields are at their lowest since early March...\nSource: Bloomberg\nAnd Japanese equity markets are none too happy with Powell's policy error malarkey...\nSource: Bloomberg\nAsLance Roberts noted earlier,there have been ZERO times in history when the Fed started a rate hiking campaign that did not lead to a negative outcome.We suggest this time won’t be any different.","news_type":1},"isVote":1,"tweetType":1,"viewCount":752,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":167827143,"gmtCreate":1624260873982,"gmtModify":1634008746834,"author":{"id":"3581763489080929","authorId":"3581763489080929","name":"Miao94","avatar":"https://static.tigerbbs.com/34f3df2688773fe9bc20c385589224ea","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581763489080929","authorIdStr":"3581763489080929"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/167827143","repostId":"1154249454","repostType":4,"isVote":1,"tweetType":1,"viewCount":729,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":167827959,"gmtCreate":1624260863571,"gmtModify":1634008747080,"author":{"id":"3581763489080929","authorId":"3581763489080929","name":"Miao94","avatar":"https://static.tigerbbs.com/34f3df2688773fe9bc20c385589224ea","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581763489080929","authorIdStr":"3581763489080929"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/167827959","repostId":"1154249454","repostType":4,"isVote":1,"tweetType":1,"viewCount":829,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164991820,"gmtCreate":1624164162460,"gmtModify":1634009934875,"author":{"id":"3581763489080929","authorId":"3581763489080929","name":"Miao94","avatar":"https://static.tigerbbs.com/34f3df2688773fe9bc20c385589224ea","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581763489080929","authorIdStr":"3581763489080929"},"themes":[],"htmlText":"[开心]&nbsp;","listText":"[开心]&nbsp;","text":"[开心]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/164991820","repostId":"1126454279","repostType":4,"isVote":1,"tweetType":1,"viewCount":1274,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":164077801,"gmtCreate":1624163479303,"gmtModify":1634009948197,"author":{"id":"3581763489080929","authorId":"3581763489080929","name":"Miao94","avatar":"https://static.tigerbbs.com/34f3df2688773fe9bc20c385589224ea","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581763489080929","authorIdStr":"3581763489080929"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/164077801","repostId":"1192473918","repostType":4,"repost":{"id":"1192473918","kind":"news","pubTimestamp":1624029343,"share":"https://www.laohu8.com/m/news/1192473918?lang=&edition=full","pubTime":"2021-06-18 23:15","market":"us","language":"en","title":"PLTR Stock: The Palantir-FAA Deal News Should Have Investors Smiling Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1192473918","media":"investorplace","summary":"Palantir Technologies(NYSE:PLTR) stock is on the move Friday following news of a deal with the Feder","content":"<p><b>Palantir Technologies</b>(NYSE:<b><u>PLTR</u></b>) stock is on the move Friday following news of a deal with the Federal Aviation Administration (FAA).</p>\n<p>The goal of this deal is toassist the FAA in modernizing its ” objectives for aviation safety.”This will have Palantir Technologies providing the agency with a data analyzing tool to help with that effort.</p>\n<p>According to a news release, this will have Palantir Technologies monitoring various safety aspects for the FAA. That includes reintegrating the 737 MAX fleet back into service after it was suspended due to fatal crashes.</p>\n<p>Palantir Technologies’ deal with the FAA is set to last for one year. However, there’s also the option to extend it by up to two years. The agreement has a maximum value of $18.4 million.</p>\n<p>Akash Jain, president of Palantir USG, said the following about the agreement with the FAA that should have PLTR stock gaining today.</p>\n<blockquote>\n “We are proud to be partnering with the Federal Aviation Administration to support their critical safety mission.”\n</blockquote>\n<p>The fact that PLTR stock is actually moving lower today despite this news is strange. The company’s shares did start off rising in early morning trading, but quickly fell back down to yesterday’s close before dipping even lower.</p>\n<p>It’s also worth noting that trading volume isn’t taking off on news of the FAA deal, either. As of this writing, more than 20 million shares of PLTR stock had changed hands. That’s still well below the company’s daily average trading volume of 57.8 million shares.</p>\n<p>PLTR stock was down 1.1% as of Friday morning.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PLTR Stock: The Palantir-FAA Deal News Should Have Investors Smiling Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPLTR Stock: The Palantir-FAA Deal News Should Have Investors Smiling Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-18 23:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/pltr-stock-the-palantir-faa-deal-news-should-have-investors-smiling-today/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Palantir Technologies(NYSE:PLTR) stock is on the move Friday following news of a deal with the Federal Aviation Administration (FAA).\nThe goal of this deal is toassist the FAA in modernizing its ” ...</p>\n\n<a href=\"https://investorplace.com/2021/06/pltr-stock-the-palantir-faa-deal-news-should-have-investors-smiling-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://investorplace.com/2021/06/pltr-stock-the-palantir-faa-deal-news-should-have-investors-smiling-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1192473918","content_text":"Palantir Technologies(NYSE:PLTR) stock is on the move Friday following news of a deal with the Federal Aviation Administration (FAA).\nThe goal of this deal is toassist the FAA in modernizing its ” objectives for aviation safety.”This will have Palantir Technologies providing the agency with a data analyzing tool to help with that effort.\nAccording to a news release, this will have Palantir Technologies monitoring various safety aspects for the FAA. That includes reintegrating the 737 MAX fleet back into service after it was suspended due to fatal crashes.\nPalantir Technologies’ deal with the FAA is set to last for one year. However, there’s also the option to extend it by up to two years. The agreement has a maximum value of $18.4 million.\nAkash Jain, president of Palantir USG, said the following about the agreement with the FAA that should have PLTR stock gaining today.\n\n “We are proud to be partnering with the Federal Aviation Administration to support their critical safety mission.”\n\nThe fact that PLTR stock is actually moving lower today despite this news is strange. The company’s shares did start off rising in early morning trading, but quickly fell back down to yesterday’s close before dipping even lower.\nIt’s also worth noting that trading volume isn’t taking off on news of the FAA deal, either. As of this writing, more than 20 million shares of PLTR stock had changed hands. That’s still well below the company’s daily average trading volume of 57.8 million shares.\nPLTR stock was down 1.1% as of Friday morning.","news_type":1},"isVote":1,"tweetType":1,"viewCount":654,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164049649,"gmtCreate":1624162617681,"gmtModify":1634009964297,"author":{"id":"3581763489080929","authorId":"3581763489080929","name":"Miao94","avatar":"https://static.tigerbbs.com/34f3df2688773fe9bc20c385589224ea","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581763489080929","authorIdStr":"3581763489080929"},"themes":[],"htmlText":"Great&nbsp;","listText":"Great&nbsp;","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/164049649","repostId":"1175119628","repostType":4,"isVote":1,"tweetType":1,"viewCount":760,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164057829,"gmtCreate":1624162517661,"gmtModify":1634009965847,"author":{"id":"3581763489080929","authorId":"3581763489080929","name":"Miao94","avatar":"https://static.tigerbbs.com/34f3df2688773fe9bc20c385589224ea","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581763489080929","authorIdStr":"3581763489080929"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/164057829","repostId":"1103331073","repostType":4,"isVote":1,"tweetType":1,"viewCount":819,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":165112950,"gmtCreate":1624105392170,"gmtModify":1634010651824,"author":{"id":"3581763489080929","authorId":"3581763489080929","name":"Miao94","avatar":"https://static.tigerbbs.com/34f3df2688773fe9bc20c385589224ea","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581763489080929","authorIdStr":"3581763489080929"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/165112950","repostId":"2144775875","repostType":4,"isVote":1,"tweetType":1,"viewCount":822,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166554781,"gmtCreate":1624019545543,"gmtModify":1634024045441,"author":{"id":"3581763489080929","authorId":"3581763489080929","name":"Miao94","avatar":"https://static.tigerbbs.com/34f3df2688773fe9bc20c385589224ea","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581763489080929","authorIdStr":"3581763489080929"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/166554781","repostId":"1158784745","repostType":4,"repost":{"id":"1158784745","kind":"news","pubTimestamp":1624017454,"share":"https://www.laohu8.com/m/news/1158784745?lang=&edition=full","pubTime":"2021-06-18 19:57","market":"sh","language":"en","title":"Inflation breakout will drive 10-year Treasury yields above 2% in coming months, Wells Fargo predicts","url":"https://stock-news.laohu8.com/highlight/detail?id=1158784745","media":"cnbc","summary":"Treasury yields may be about to break out.\nEven though yields temporarily fell after this week's Fed","content":"<div>\n<p>Treasury yields may be about to break out.\nEven though yields temporarily fell after this week's Federal Reserve decision on interest rates, Wells Fargo Securities' Michael Schumacher expects the ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/18/inflation-breakout-will-soon-drive-10-year-yields-above-2percent-wells-fargo.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inflation breakout will drive 10-year Treasury yields above 2% in coming months, Wells Fargo predicts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInflation breakout will drive 10-year Treasury yields above 2% in coming months, Wells Fargo predicts\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-18 19:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/18/inflation-breakout-will-soon-drive-10-year-yields-above-2percent-wells-fargo.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Treasury yields may be about to break out.\nEven though yields temporarily fell after this week's Federal Reserve decision on interest rates, Wells Fargo Securities' Michael Schumacher expects the ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/18/inflation-breakout-will-soon-drive-10-year-yields-above-2percent-wells-fargo.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index"},"source_url":"https://www.cnbc.com/2021/06/18/inflation-breakout-will-soon-drive-10-year-yields-above-2percent-wells-fargo.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1158784745","content_text":"Treasury yields may be about to break out.\nEven though yields temporarily fell after this week's Federal Reserve decision on interest rates, Wells Fargo Securities' Michael Schumacher expects the benchmark 10-year Treasury Note rate to end the year as high as 2.20%.\n\"The 10-year yield is going up a fair bit through the remainder of the year,\" the firm's head of macro strategy told CNBC's \"Trading Nation\" on Thursday. \"Not a steady rise to be sure. But we do think there's a pretty strong bear case to be made over the next six [to] seven months.\"\nSchumacherattributes the inflation comeback for his forecast— with an emphasis on the next 12 months.\n\"Core PCEwhich the Fed likes to look at is above 3% for the next year. It's an amazing number. We have not seen inflation like that in the U.S. on a sustained basis for a very long time,\" he said. \"This really gets at what the people in the market are focused on: Just how long is that inflation spike going to last? Is it transient? Is it transitory? I don't know. But it's troubling, that's pretty clear.\"\nIn his post-Fed decision research note, Schumacher said the Fed is still coming to terms with the inflation spike. According to Schumacher, the biggest risk facing the bond market and economy is the Fed's potential response to the strong economic comeback. If the Fed gets spooked, it would likely hike rates next year instead of waiting until at least 2023.\nSo far, Schumacher's bond market outlook is on target.\nComing into 2021, Schumacher predicted the10-year yieldwould hit 1.15% to 1.35% by this year's halfway point — with the caveat it could reach as high as 1.50%. He made the forecast when the yield was below 1% and months before the Covid-19 vaccines were widely available.\nOn Thursday, the 10-year yield closed at 1.51%. It's up almost 4% over the past week, but down 8% over the past three months.\nHe also doubts the dollar, which initially surged on a more hawkish Fed, will continue to extend its gains.\n\"For the first quarter of this year, the U.S. and arguably the U.K. had a tremendous advantage over most of the Western world in terms of Covid vaccinations. Now, a lot of countries are catching up, and you could view that as a proxy for future economic activity,\" Schumacher said. \"Thedollaris losing some of those tailwinds.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":627,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":168563539,"gmtCreate":1623978866321,"gmtModify":1634024876165,"author":{"id":"3581763489080929","authorId":"3581763489080929","name":"Miao94","avatar":"https://static.tigerbbs.com/34f3df2688773fe9bc20c385589224ea","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581763489080929","authorIdStr":"3581763489080929"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/168563539","repostId":"2144411077","repostType":4,"isVote":1,"tweetType":1,"viewCount":303,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":168569542,"gmtCreate":1623978843086,"gmtModify":1634024877216,"author":{"id":"3581763489080929","authorId":"3581763489080929","name":"Miao94","avatar":"https://static.tigerbbs.com/34f3df2688773fe9bc20c385589224ea","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581763489080929","authorIdStr":"3581763489080929"},"themes":[],"htmlText":"Go go go","listText":"Go go go","text":"Go go go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/168569542","repostId":"1140460323","repostType":4,"isVote":1,"tweetType":1,"viewCount":205,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":168560878,"gmtCreate":1623978813294,"gmtModify":1634024878653,"author":{"id":"3581763489080929","authorId":"3581763489080929","name":"Miao94","avatar":"https://static.tigerbbs.com/34f3df2688773fe9bc20c385589224ea","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581763489080929","authorIdStr":"3581763489080929"},"themes":[],"htmlText":"Sad","listText":"Sad","text":"Sad","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/168560878","repostId":"2144744636","repostType":4,"repost":{"id":"2144744636","kind":"news","pubTimestamp":1623940250,"share":"https://www.laohu8.com/m/news/2144744636?lang=&edition=full","pubTime":"2021-06-17 22:30","market":"sg","language":"en","title":"Low dosage may be behind low efficacy of CureVac vaccine: Study leader","url":"https://stock-news.laohu8.com/highlight/detail?id=2144744636","media":"The Straits Times","summary":"BERLIN (REUTERS) - The low dosage might be a key reason why CureVac's Covid-19 vaccine reported disa","content":"<div>\n<p>BERLIN (REUTERS) - The low dosage might be a key reason why CureVac's Covid-19 vaccine reported disappointing efficacy in a pivotal late-stage trial, the scientist leading the study of the shot said ...</p>\n\n<a href=\"http://www.straitstimes.com/world/europe/low-dosage-may-be-behind-low-efficacy-of-curevac-vaccine-study-leader\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Low dosage may be behind low efficacy of CureVac vaccine: Study leader</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLow dosage may be behind low efficacy of CureVac vaccine: Study leader\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 22:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/world/europe/low-dosage-may-be-behind-low-efficacy-of-curevac-vaccine-study-leader><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BERLIN (REUTERS) - The low dosage might be a key reason why CureVac's Covid-19 vaccine reported disappointing efficacy in a pivotal late-stage trial, the scientist leading the study of the shot said ...</p>\n\n<a href=\"http://www.straitstimes.com/world/europe/low-dosage-may-be-behind-low-efficacy-of-curevac-vaccine-study-leader\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"http://www.straitstimes.com/world/europe/low-dosage-may-be-behind-low-efficacy-of-curevac-vaccine-study-leader","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2144744636","content_text":"BERLIN (REUTERS) - The low dosage might be a key reason why CureVac's Covid-19 vaccine reported disappointing efficacy in a pivotal late-stage trial, the scientist leading the study of the shot said on Thursday (June 17).\nThe German biotech's vaccine proved only 47 per cent effective in an initial trial, far lower than those of rivals BioNTech/Pfizer and Moderna, which are also based on mRNA technology and had efficacy rates well above 90 per cent.\nDr Peter Kremsner from the University Hospital in Tuebingen which is running the trial, told Reuters the low efficacy is \"very likely due to the dose\".\nUnlike BioNTech and Moderna, CureVac did not modify the mRNA used in the shots and therefore a higher dosage was not possible because of the side effects to be expected, Dr Kremsner said.\nWith just 12 micrograms of mRNA per dose, the company has been seeking to position itself as a low-dose alternative to BioNTech and Moderna's established shots with 30 and 100 micrograms per shot, respectively.\nIt is also easy to store and cheaper than the other mRNA shots too.\nThe European Union has agreed to pay 12 euros (S$19.20) per dose for supplies of the shot, an EU internal document shows, but has paid more than 15 euros for the other mRNA shots.\nHowever, the interim trial analysis goes some way to challenging the expectation, which was previously reflected in the company's share price, that all mRNA vaccines are similar.\nThe news wiped as much as 52 per cent off the company's value on Thursday.\nCureVac said on Wednesday that new variants had proved a headwind, but data from BioNTech and Moderna have, however, so far suggested only somewhat weaker protection against new variants.\nDr Kremsner said he thought it was probably a \"long shot\" as to whether CureVac's vaccine might turn out to be more effective when targeting a particular variant.\nThe disappointing results are a blow since European governments had been hoping to add it to their arsenal after age limits were imposed on the use of the Johnson & Johnson and AstraZeneca vaccines due to a link to extremely rare but potentially fatal clotting disorders.","news_type":1},"isVote":1,"tweetType":1,"viewCount":142,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":168587018,"gmtCreate":1623978789034,"gmtModify":1634024880334,"author":{"id":"3581763489080929","authorId":"3581763489080929","name":"Miao94","avatar":"https://static.tigerbbs.com/34f3df2688773fe9bc20c385589224ea","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581763489080929","authorIdStr":"3581763489080929"},"themes":[],"htmlText":"[微笑]&nbsp;","listText":"[微笑]&nbsp;","text":"[微笑]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/168587018","repostId":"2144690742","repostType":4,"repost":{"id":"2144690742","kind":"news","pubTimestamp":1623942044,"share":"https://www.laohu8.com/m/news/2144690742?lang=&edition=full","pubTime":"2021-06-17 23:00","market":"us","language":"en","title":"Column: The FDA's hasty approval of a new Alzheimer's drug is looking worse than ever","url":"https://stock-news.laohu8.com/highlight/detail?id=2144690742","media":"LA Times","summary":"The FDA's decision on Aduhelm sets up a healthcare spending crisis. \nFollowing a year in which the F","content":"<p><img src=\"https://static.tigerbbs.com/5a6526be3c93006ee9d37664f7f4650b\" tg-width=\"840\" tg-height=\"560\" referrerpolicy=\"no-referrer\">The FDA's decision on Aduhelm sets up a healthcare spending crisis.&nbsp;</p>\n<p>Following a year in which the Food and Drug Administration meekly allowed President Trump to denigrate its integrity and undermine its judgment, it wasn't clear that the agency could fall even lower in public and professional esteem.</p>\n<p>It's clear now. The FDA's widely criticized decision on June 7 to approve the new Alzheimer's drug Aduhelm despite a nearly complete absence of evidence that it works is looking worse and worse with every day that passes.</p>\n<p>The latest data point underscoring the disastrous consequences of the FDA approval is related to the sky-high average price of $56,000 a year for the drug set by its U.S. manufacturer, Biogen.</p>\n<blockquote>\n The limited evidence for the efficacy of Aduhelm raises the question of whether its large impact on health spending is justified.\n</blockquote>\n<p>Altarum consultants</p>\n<p>According to a report by the nonprofit healthcare consulting organization Altarum, if the drug is prescribed for only 1 million patients a year — the low end of Biogen's marketing expectations — by the mid-2020s it will account for more than 1% of all national health spending. In 2025, for instance, when total spending is expected to reach abut $5.3 trillion, $57 billion of that will be spent on Aduhelm.</p>\n<p>The drug will increase all prescription drug spending by 8% and non-retail drug spending — that is, for drugs that have to be administered in hospitals or doctors' offices — by 25%. If the patient caseload doubles, so will those figures. And the FDA's approval would allow Aduhelm to be prescribed for any of the nation's Alzheimer's patients, who currently number more than 6 million.</p>\n<p>That will impose higher costs on 56 million Americans enrolled in Medicare Part B even if they don't suffer from Alzheimer's, the Kaiser Family Foundation observes. That's because Medicare is required by law to cover all prescription medicines approved by the FDA. Part B premiums rise with Medicare's expenses, so the higher spending on Adulhelm will hit all premium payers in the pocketbook.</p>\n<p>If 1 million Part B members take Aduhelm, the program's 80% share of the drug's cost would come to nearly $45 billion, or well more than the $37 billion Medicare paid for all Part B drugs in 2019.</p>\n<p>Many Medicare patients taking the drug will be hard-pressed to afford it, KFF notes. Their 20%, uncapped share of Part B drug and services costs would mean an average bill of $11,200 per year for the drug. That's almost 40% of the $29,650 median income of Medicare Part B members.</p>\n<p>It gets worse. Altarum's estimates don't encompass the ancillary costs that will be associated with taking Aduhelm. Because the clinical trials revealed that about 30% of patients receiving a high dose of the drug experienced brain swelling, patients will have to undergo regular MRI tests to watch out for this dangerous side effect. They'll have to pay their share of that, too.</p>\n<p>This isn't the first time that a new drug has threatened to break the national healthcare bank. The best comparison may be the hepatitis-C drugs Sovaldi and Harvoni, which were priced by their developer, Gilead, at $84,000 and nearly $100,000 per year, respectively.</p>\n<p>Those drugs drove annual growth in retail prescription spending from 2.2% in 2013 to 13.5% in 2014, after their introduction, Altarum says.</p>\n<p>But there are differences. Sovaldi and Harvoni cured more than 90% of hepatitis-C patients after a single round of treatment, so the spending on any patient lasted less than a year; measuring their cost against the cost of treating hepatitis-C patients indefinitely made the cost-benefit balance obvious. Indeed, by 2016, when most patients had been treated, the prescription growth rate fell back to 1.7%,</p>\n<p>But Aduhelm is neither a cure nor a <a href=\"https://laohu8.com/S/AONE\">one</a>-time treatment. \"Aduhelm is to be administered repeatedly throughout the patient’s lifetime or until the patient and his or her physician elect to discontinue treatment,\" Altarum explains. \"The resultant growth in spending will therefore be sustained for the foreseeable future.\"</p>\n<p>The organization's bottom line: \"The limited evidence for the efficacy of Aduhelm raises the question of whether its large impact on health spending is justified.\"</p>\n<p>As bad as the FDA's decision is looking today, it didn't start out as a widely praised action, either. As we reported last week, <a href=\"https://laohu8.com/S/AONE.U\">one</a> member of the FDA scientific advisory committee that had examined results from the drug's clinical trials pronounced the action \"probably the worst drug approval decision in recent U.S. history” in a letter resigning from the committee.</p>\n<p>The 11-member committee had advised almost unanimously against the approval. <a href=\"https://laohu8.com/S/TWOA.U\">Two</a> other members also resigned after the FDA ignored the panel's recommendation.</p>\n<p>Alzheimer's specialists are concerned about the FDA decision for more than financial reasons. They fear that the existence of a drug with the FDA's imprimatur, as questionable as it is, will interfere with efforts to develop and test other treatments that may turn out to be more promising.</p>\n<p>Patients may be reluctant to enroll in trials of alternative drugs instead of taking Aduhelm, for example. And researchers trying to recruit trial subjects will have to reject anyone who has been treated with Aduhelm, because it will be difficult, if not impossible, to determine whether a given result is due to Aduhelm or the new drug.</p>\n<p>The longest-lasting effect, however, may be on the FDA's reputation for imposing rigorous safety and efficacy standards. The pharmaceutical industry has long groused about the agency's painstaking approval process, even though it has given the American drug market an image as the safest in the world.</p>\n<p>The drugmakers have consistently pushed for faster approvals and the acceptance of ever more sketchy evidence from clinical trials.</p>\n<p>Aaron S. Kesselheim, the Harvard professor who delivered that damning judgment about the FDA approval before resigning from its advisory panel, has called for the creation of a new agency to oversee drug approvals, presumably inoculated from pressure from Big Pharma.</p>\n<p>The FDA's approval of a high-priced, apparently low-value drug that will yield billions of dollars in profits for its manufacturer may even spur Congress finally to take America's drug-price crisis in hand and find a solution. That could be the silver lining around the cloud of the FDA's action.</p>\n<p>But it will be a shame that an agency that reigned as a bulwark against unsafe and ineffective drugs since its founding in 1906 had to fall so low to achieve that goal.</p>\n<p>This story originally appeared in Los Angeles Times.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Column: The FDA's hasty approval of a new Alzheimer's drug is looking worse than ever</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nColumn: The FDA's hasty approval of a new Alzheimer's drug is looking worse than ever\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 23:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/column-fdas-hasty-approval-alzheimers-144244083.html><strong>LA Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The FDA's decision on Aduhelm sets up a healthcare spending crisis. \nFollowing a year in which the Food and Drug Administration meekly allowed President Trump to denigrate its integrity and undermine ...</p>\n\n<a href=\"https://finance.yahoo.com/news/column-fdas-hasty-approval-alzheimers-144244083.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://finance.yahoo.com/news/column-fdas-hasty-approval-alzheimers-144244083.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2144690742","content_text":"The FDA's decision on Aduhelm sets up a healthcare spending crisis. \nFollowing a year in which the Food and Drug Administration meekly allowed President Trump to denigrate its integrity and undermine its judgment, it wasn't clear that the agency could fall even lower in public and professional esteem.\nIt's clear now. The FDA's widely criticized decision on June 7 to approve the new Alzheimer's drug Aduhelm despite a nearly complete absence of evidence that it works is looking worse and worse with every day that passes.\nThe latest data point underscoring the disastrous consequences of the FDA approval is related to the sky-high average price of $56,000 a year for the drug set by its U.S. manufacturer, Biogen.\n\n The limited evidence for the efficacy of Aduhelm raises the question of whether its large impact on health spending is justified.\n\nAltarum consultants\nAccording to a report by the nonprofit healthcare consulting organization Altarum, if the drug is prescribed for only 1 million patients a year — the low end of Biogen's marketing expectations — by the mid-2020s it will account for more than 1% of all national health spending. In 2025, for instance, when total spending is expected to reach abut $5.3 trillion, $57 billion of that will be spent on Aduhelm.\nThe drug will increase all prescription drug spending by 8% and non-retail drug spending — that is, for drugs that have to be administered in hospitals or doctors' offices — by 25%. If the patient caseload doubles, so will those figures. And the FDA's approval would allow Aduhelm to be prescribed for any of the nation's Alzheimer's patients, who currently number more than 6 million.\nThat will impose higher costs on 56 million Americans enrolled in Medicare Part B even if they don't suffer from Alzheimer's, the Kaiser Family Foundation observes. That's because Medicare is required by law to cover all prescription medicines approved by the FDA. Part B premiums rise with Medicare's expenses, so the higher spending on Adulhelm will hit all premium payers in the pocketbook.\nIf 1 million Part B members take Aduhelm, the program's 80% share of the drug's cost would come to nearly $45 billion, or well more than the $37 billion Medicare paid for all Part B drugs in 2019.\nMany Medicare patients taking the drug will be hard-pressed to afford it, KFF notes. Their 20%, uncapped share of Part B drug and services costs would mean an average bill of $11,200 per year for the drug. That's almost 40% of the $29,650 median income of Medicare Part B members.\nIt gets worse. Altarum's estimates don't encompass the ancillary costs that will be associated with taking Aduhelm. Because the clinical trials revealed that about 30% of patients receiving a high dose of the drug experienced brain swelling, patients will have to undergo regular MRI tests to watch out for this dangerous side effect. They'll have to pay their share of that, too.\nThis isn't the first time that a new drug has threatened to break the national healthcare bank. The best comparison may be the hepatitis-C drugs Sovaldi and Harvoni, which were priced by their developer, Gilead, at $84,000 and nearly $100,000 per year, respectively.\nThose drugs drove annual growth in retail prescription spending from 2.2% in 2013 to 13.5% in 2014, after their introduction, Altarum says.\nBut there are differences. Sovaldi and Harvoni cured more than 90% of hepatitis-C patients after a single round of treatment, so the spending on any patient lasted less than a year; measuring their cost against the cost of treating hepatitis-C patients indefinitely made the cost-benefit balance obvious. Indeed, by 2016, when most patients had been treated, the prescription growth rate fell back to 1.7%,\nBut Aduhelm is neither a cure nor a one-time treatment. \"Aduhelm is to be administered repeatedly throughout the patient’s lifetime or until the patient and his or her physician elect to discontinue treatment,\" Altarum explains. \"The resultant growth in spending will therefore be sustained for the foreseeable future.\"\nThe organization's bottom line: \"The limited evidence for the efficacy of Aduhelm raises the question of whether its large impact on health spending is justified.\"\nAs bad as the FDA's decision is looking today, it didn't start out as a widely praised action, either. As we reported last week, one member of the FDA scientific advisory committee that had examined results from the drug's clinical trials pronounced the action \"probably the worst drug approval decision in recent U.S. history” in a letter resigning from the committee.\nThe 11-member committee had advised almost unanimously against the approval. Two other members also resigned after the FDA ignored the panel's recommendation.\nAlzheimer's specialists are concerned about the FDA decision for more than financial reasons. They fear that the existence of a drug with the FDA's imprimatur, as questionable as it is, will interfere with efforts to develop and test other treatments that may turn out to be more promising.\nPatients may be reluctant to enroll in trials of alternative drugs instead of taking Aduhelm, for example. And researchers trying to recruit trial subjects will have to reject anyone who has been treated with Aduhelm, because it will be difficult, if not impossible, to determine whether a given result is due to Aduhelm or the new drug.\nThe longest-lasting effect, however, may be on the FDA's reputation for imposing rigorous safety and efficacy standards. The pharmaceutical industry has long groused about the agency's painstaking approval process, even though it has given the American drug market an image as the safest in the world.\nThe drugmakers have consistently pushed for faster approvals and the acceptance of ever more sketchy evidence from clinical trials.\nAaron S. Kesselheim, the Harvard professor who delivered that damning judgment about the FDA approval before resigning from its advisory panel, has called for the creation of a new agency to oversee drug approvals, presumably inoculated from pressure from Big Pharma.\nThe FDA's approval of a high-priced, apparently low-value drug that will yield billions of dollars in profits for its manufacturer may even spur Congress finally to take America's drug-price crisis in hand and find a solution. That could be the silver lining around the cloud of the FDA's action.\nBut it will be a shame that an agency that reigned as a bulwark against unsafe and ineffective drugs since its founding in 1906 had to fall so low to achieve that goal.\nThis story originally appeared in Los Angeles Times.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1028,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":168583238,"gmtCreate":1623978685324,"gmtModify":1634024886525,"author":{"id":"3581763489080929","authorId":"3581763489080929","name":"Miao94","avatar":"https://static.tigerbbs.com/34f3df2688773fe9bc20c385589224ea","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581763489080929","authorIdStr":"3581763489080929"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/168583238","repostId":"2144742686","repostType":4,"isVote":1,"tweetType":1,"viewCount":178,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":168589416,"gmtCreate":1623978669035,"gmtModify":1634024887332,"author":{"id":"3581763489080929","authorId":"3581763489080929","name":"Miao94","avatar":"https://static.tigerbbs.com/34f3df2688773fe9bc20c385589224ea","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581763489080929","authorIdStr":"3581763489080929"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/168589416","repostId":"2144742686","repostType":4,"isVote":1,"tweetType":1,"viewCount":498,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":168512345,"gmtCreate":1623978542587,"gmtModify":1634024892830,"author":{"id":"3581763489080929","authorId":"3581763489080929","name":"Miao94","avatar":"https://static.tigerbbs.com/34f3df2688773fe9bc20c385589224ea","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581763489080929","authorIdStr":"3581763489080929"},"themes":[],"htmlText":"Comments&nbsp;","listText":"Comments&nbsp;","text":"Comments","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/168512345","repostId":"2144286417","repostType":4,"isVote":1,"tweetType":1,"viewCount":154,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":168516150,"gmtCreate":1623978518070,"gmtModify":1634024893887,"author":{"id":"3581763489080929","authorId":"3581763489080929","name":"Miao94","avatar":"https://static.tigerbbs.com/34f3df2688773fe9bc20c385589224ea","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581763489080929","authorIdStr":"3581763489080929"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/168516150","repostId":"2144286417","repostType":4,"isVote":1,"tweetType":1,"viewCount":275,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":168513377,"gmtCreate":1623978452899,"gmtModify":1634024896749,"author":{"id":"3581763489080929","authorId":"3581763489080929","name":"Miao94","avatar":"https://static.tigerbbs.com/34f3df2688773fe9bc20c385589224ea","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581763489080929","authorIdStr":"3581763489080929"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/168513377","repostId":"1140460323","repostType":4,"isVote":1,"tweetType":1,"viewCount":248,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":168519834,"gmtCreate":1623978435628,"gmtModify":1634024897560,"author":{"id":"3581763489080929","authorId":"3581763489080929","name":"Miao94","avatar":"https://static.tigerbbs.com/34f3df2688773fe9bc20c385589224ea","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581763489080929","authorIdStr":"3581763489080929"},"themes":[],"htmlText":"Comment&nbsp;","listText":"Comment&nbsp;","text":"Comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/168519834","repostId":"1197275653","repostType":4,"repost":{"id":"1197275653","kind":"news","pubTimestamp":1623976968,"share":"https://www.laohu8.com/m/news/1197275653?lang=&edition=full","pubTime":"2021-06-18 08:42","market":"us","language":"en","title":"Downtrodden Okta Stock Still Has a Chance to Shine Again","url":"https://stock-news.laohu8.com/highlight/detail?id=1197275653","media":"InvestorPlace","summary":"OKTA stock is a well-positioned player in the increasingly hot cybersecurity space\nIn May 2021, mult","content":"<p>OKTA stock is a well-positioned player in the increasingly hot cybersecurity space</p>\n<p>In May 2021, multiple accounts associated with hacking group DarkSide received $4.4 million worth of ransom in&nbsp;<b>Bitcoin</b>(CCC:<b><u>BTC-USD</u></b>) after a cyberattack on the Colonial Pipeline. The impact of this attack led to a significant increase in gas prices. It also left some stations on the East Coast empty for a period. Ultimately, this event thrust&nbsp;cybersecurity stocks&nbsp;like<b>&nbsp;Okta</b>(NASDAQ:<b><u>OKTA</u></b>) stock back into the spotlight.</p>\n<p>You might be quick to add OKTA stock to your list of cybersecurity companies to buy after this attack. After all, it’s a company that specializes in identity security. However, the bullish case doesn’t come without some challenges.</p>\n<p>So, here’s a closer look at whether Okta is worth buying in 2021.</p>\n<p><b>OKTA Stock Has Ongoing Advantages</b></p>\n<p>While some investing trends come and go (just take a look at the whacky ridememe stockshave been going on), one thing is guaranteed moving forward. Cybersecurity — and the companies that specialize in the space — will&nbsp;remain&nbsp;<i>invaluable</i>.</p>\n<p>In our increasingly hyper-connected world, the need for digital security services has no end. When it comes to Okta’s offerings in this space, it provides&nbsp;high-quality security solutions&nbsp;to identity protection.</p>\n<p>Breaking it down a bit further, the company offers a&nbsp;cloud-based security system&nbsp;that’s capable of intertwining with on-site applications. It’s designed to support modern work-based ecosystems that frequently rely on a combination of multiple cloud applications, user devices like laptops and phones, as well as external users’ (customers or business partners) systems and&nbsp;own custom apps.</p>\n<p>The more “inhabitants” in the ecosystem, the greater the number of security risks it carries (and the more complex it becomes for IT teams to handle). So, rather than require multiple logins for each element and user, Okta links them through a single sign-on using its secure process. Okta also allows you to combine multi-factor authentication functionality with its customizable “Universal Directory.” Essentially, this helps IT teams determine the level of access per user within the entire system.</p>\n<p>That’s a super fancy way of saying Okta’s services are a strong solution to your modern IT team’s day-to-day problems. According to the company, it enables companies to “[overcome] the economic and technological limitations of any legacy identity management scheme […] [they] are currently using.”</p>\n<p>This is all highly relevant to the investment thesis behind OKTA stock. After all, its unique security solution is the lifeblood of the company’s future. And that future is bright.</p>\n<p>With the onset of an increasingly remote workforce upon us, alongside the arrival of a“Cyber Pandemic,”— both of which were byproducts of the social impact of Covid-19 — IT solutions should remain hot commodities long-term. Consider the following:</p>\n<ul>\n <li>“The percentage of workers permanently working from home is&nbsp;expected to doublein 2021.”</li>\n <li>“Worldwide cybercrime costs will hit&nbsp;$6 trillion annually by 2021.”</li>\n <li>“Security services accounted for an estimated 50% of cybersecurity budgets in 2020.”</li>\n <li>Looking at the frequency of ransomware attacks alone, the rate has increased from one every 40 seconds in 2016 to an attack&nbsp;every 11 seconds in 2021.</li>\n</ul>\n<p>Clearly, companies are now willing to fork out the dough to stay safe. And the need for this safety is only growing. All of this should keep Okta in business for years to come. It should also help drive OKTA stock over a longer-term time frame.</p>\n<p>But, as with most investment cases, things aren’t&nbsp;<i>that</i>&nbsp;simple.</p>\n<p><b>The Downsides with Okta</b></p>\n<p>While OKTA stock had a strong run in 2020 (a 115% increase), it’s down about 10% so far in 2021. Much of that could be attributed to the pandemic catalyst tapering off. However, slowing revenue growth is another likely cause.</p>\n<p>Last year, Okta experienced massive 40% growth. The company now&nbsp;projects 30% revenue growth&nbsp;for next year. As<i>The Motley Fool’s</i>&nbsp;Travis Hoium&nbsp;explains, “with&nbsp;growth stocks, any reduction in the expected growth rate of the company can cause shares to plummet.”</p>\n<p>The difference between 30% and 40% growth might not seem significant to some. However, several analysts issued price-target downgrades on the news earlier this year. Piper Sandler issued a cut to $235 from their $250 price target (a 6% reduction). Likewise, BMO Capital Markets changed its target from $285 to $265 (a 7% reduction).</p>\n<p>The reduced growth projections (alongside dwindling post-pandemic hype) is a large reason for Okta’s pain in 2021. But there are also valuation concerns to contend with. At the start of the year, tech stocks suffered a selloff. Much of that’s due to inflated valuations within the space and continuing&nbsp;concerns that we’re in a tech bubble.</p>\n<p>Whether or not you agree with that broader market assessment, many argue that the valuation for OKTA stock is&nbsp;pricey relative to its peers. Plus, this concern gains further traction when you consider the following: “More than 70 percent&nbsp;of security executives believe that their budgets for fiscal year 2021 will shrink.” If these executives are correct, that could intensify the prospective reduction in Okta’s growth.</p>\n<p><b>Is OKTA Stock an Ugly Buy?</b></p>\n<p>That certainly puts a dent in the bullish case for OKTA stock. But I don’t think it should be taken as a sign of complete doom.</p>\n<p>When it comes to Okta, there’s nothing exceptionally<i>ugly</i>about the company. However, the valuation and growth concerns are legitimate, depending on what you expect from the stock. As such, there are at least two core questions to ask yourself moving forward:</p>\n<ul>\n <li><b>Do you expect Okta to continue growing near the 40% rate it enjoyed last year?</b>Okta projects a 10% reduction in growth and this coincides with the anticipated reduction in security budgets for 2021 (70%-plus of executives expect this to happen). If you’re looking for Okta to keep growing at a higher rate, then it might be time to walk away.</li>\n <li><b>Do you believe in Okta’s long-term viability?</b>As mentioned earlier, the world is only getting more remote and IT security systems are only getting more intricate and necessary. Okta is a key player in this space and its services are generally well-regarded. If it continues to produce high-quality solutions, the company should have a strong foundation for continued growth (albeit at a less impressive rate).</li>\n</ul>\n<p>Ultimately, when it comes to OKTA stock, I don’t think there’s reason to drop it. Unless, of course, you’re seeking more impressive growth narratives. Moving forward, longer-term investors ought to pay close attention to its continued viability to compete successfully in the cybersecurity space.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Downtrodden Okta Stock Still Has a Chance to Shine Again</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDowntrodden Okta Stock Still Has a Chance to Shine Again\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-18 08:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/downtrodden-okta-stock-still-has-chance-to-shine-again/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>OKTA stock is a well-positioned player in the increasingly hot cybersecurity space\nIn May 2021, multiple accounts associated with hacking group DarkSide received $4.4 million worth of ransom in ...</p>\n\n<a href=\"https://investorplace.com/2021/06/downtrodden-okta-stock-still-has-chance-to-shine-again/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OKTA":"Okta Inc."},"source_url":"https://investorplace.com/2021/06/downtrodden-okta-stock-still-has-chance-to-shine-again/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197275653","content_text":"OKTA stock is a well-positioned player in the increasingly hot cybersecurity space\nIn May 2021, multiple accounts associated with hacking group DarkSide received $4.4 million worth of ransom in Bitcoin(CCC:BTC-USD) after a cyberattack on the Colonial Pipeline. The impact of this attack led to a significant increase in gas prices. It also left some stations on the East Coast empty for a period. Ultimately, this event thrust cybersecurity stocks like Okta(NASDAQ:OKTA) stock back into the spotlight.\nYou might be quick to add OKTA stock to your list of cybersecurity companies to buy after this attack. After all, it’s a company that specializes in identity security. However, the bullish case doesn’t come without some challenges.\nSo, here’s a closer look at whether Okta is worth buying in 2021.\nOKTA Stock Has Ongoing Advantages\nWhile some investing trends come and go (just take a look at the whacky ridememe stockshave been going on), one thing is guaranteed moving forward. Cybersecurity — and the companies that specialize in the space — will remain invaluable.\nIn our increasingly hyper-connected world, the need for digital security services has no end. When it comes to Okta’s offerings in this space, it provides high-quality security solutions to identity protection.\nBreaking it down a bit further, the company offers a cloud-based security system that’s capable of intertwining with on-site applications. It’s designed to support modern work-based ecosystems that frequently rely on a combination of multiple cloud applications, user devices like laptops and phones, as well as external users’ (customers or business partners) systems and own custom apps.\nThe more “inhabitants” in the ecosystem, the greater the number of security risks it carries (and the more complex it becomes for IT teams to handle). So, rather than require multiple logins for each element and user, Okta links them through a single sign-on using its secure process. Okta also allows you to combine multi-factor authentication functionality with its customizable “Universal Directory.” Essentially, this helps IT teams determine the level of access per user within the entire system.\nThat’s a super fancy way of saying Okta’s services are a strong solution to your modern IT team’s day-to-day problems. According to the company, it enables companies to “[overcome] the economic and technological limitations of any legacy identity management scheme […] [they] are currently using.”\nThis is all highly relevant to the investment thesis behind OKTA stock. After all, its unique security solution is the lifeblood of the company’s future. And that future is bright.\nWith the onset of an increasingly remote workforce upon us, alongside the arrival of a“Cyber Pandemic,”— both of which were byproducts of the social impact of Covid-19 — IT solutions should remain hot commodities long-term. Consider the following:\n\n“The percentage of workers permanently working from home is expected to doublein 2021.”\n“Worldwide cybercrime costs will hit $6 trillion annually by 2021.”\n“Security services accounted for an estimated 50% of cybersecurity budgets in 2020.”\nLooking at the frequency of ransomware attacks alone, the rate has increased from one every 40 seconds in 2016 to an attack every 11 seconds in 2021.\n\nClearly, companies are now willing to fork out the dough to stay safe. And the need for this safety is only growing. All of this should keep Okta in business for years to come. It should also help drive OKTA stock over a longer-term time frame.\nBut, as with most investment cases, things aren’t that simple.\nThe Downsides with Okta\nWhile OKTA stock had a strong run in 2020 (a 115% increase), it’s down about 10% so far in 2021. Much of that could be attributed to the pandemic catalyst tapering off. However, slowing revenue growth is another likely cause.\nLast year, Okta experienced massive 40% growth. The company now projects 30% revenue growth for next year. AsThe Motley Fool’s Travis Hoium explains, “with growth stocks, any reduction in the expected growth rate of the company can cause shares to plummet.”\nThe difference between 30% and 40% growth might not seem significant to some. However, several analysts issued price-target downgrades on the news earlier this year. Piper Sandler issued a cut to $235 from their $250 price target (a 6% reduction). Likewise, BMO Capital Markets changed its target from $285 to $265 (a 7% reduction).\nThe reduced growth projections (alongside dwindling post-pandemic hype) is a large reason for Okta’s pain in 2021. But there are also valuation concerns to contend with. At the start of the year, tech stocks suffered a selloff. Much of that’s due to inflated valuations within the space and continuing concerns that we’re in a tech bubble.\nWhether or not you agree with that broader market assessment, many argue that the valuation for OKTA stock is pricey relative to its peers. Plus, this concern gains further traction when you consider the following: “More than 70 percent of security executives believe that their budgets for fiscal year 2021 will shrink.” If these executives are correct, that could intensify the prospective reduction in Okta’s growth.\nIs OKTA Stock an Ugly Buy?\nThat certainly puts a dent in the bullish case for OKTA stock. But I don’t think it should be taken as a sign of complete doom.\nWhen it comes to Okta, there’s nothing exceptionallyuglyabout the company. However, the valuation and growth concerns are legitimate, depending on what you expect from the stock. As such, there are at least two core questions to ask yourself moving forward:\n\nDo you expect Okta to continue growing near the 40% rate it enjoyed last year?Okta projects a 10% reduction in growth and this coincides with the anticipated reduction in security budgets for 2021 (70%-plus of executives expect this to happen). If you’re looking for Okta to keep growing at a higher rate, then it might be time to walk away.\nDo you believe in Okta’s long-term viability?As mentioned earlier, the world is only getting more remote and IT security systems are only getting more intricate and necessary. Okta is a key player in this space and its services are generally well-regarded. If it continues to produce high-quality solutions, the company should have a strong foundation for continued growth (albeit at a less impressive rate).\n\nUltimately, when it comes to OKTA stock, I don’t think there’s reason to drop it. Unless, of course, you’re seeking more impressive growth narratives. Moving forward, longer-term investors ought to pay close attention to its continued viability to compete successfully in the cybersecurity space.","news_type":1},"isVote":1,"tweetType":1,"viewCount":245,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":167827143,"gmtCreate":1624260873982,"gmtModify":1634008746834,"author":{"id":"3581763489080929","authorId":"3581763489080929","name":"Miao94","avatar":"https://static.tigerbbs.com/34f3df2688773fe9bc20c385589224ea","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581763489080929","authorIdStr":"3581763489080929"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/167827143","repostId":"1154249454","repostType":4,"isVote":1,"tweetType":1,"viewCount":729,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":168512345,"gmtCreate":1623978542587,"gmtModify":1634024892830,"author":{"id":"3581763489080929","authorId":"3581763489080929","name":"Miao94","avatar":"https://static.tigerbbs.com/34f3df2688773fe9bc20c385589224ea","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581763489080929","authorIdStr":"3581763489080929"},"themes":[],"htmlText":"Comments&nbsp;","listText":"Comments&nbsp;","text":"Comments","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/168512345","repostId":"2144286417","repostType":4,"isVote":1,"tweetType":1,"viewCount":154,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164991820,"gmtCreate":1624164162460,"gmtModify":1634009934875,"author":{"id":"3581763489080929","authorId":"3581763489080929","name":"Miao94","avatar":"https://static.tigerbbs.com/34f3df2688773fe9bc20c385589224ea","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581763489080929","authorIdStr":"3581763489080929"},"themes":[],"htmlText":"[开心]&nbsp;","listText":"[开心]&nbsp;","text":"[开心]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/164991820","repostId":"1126454279","repostType":4,"isVote":1,"tweetType":1,"viewCount":1274,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":168519834,"gmtCreate":1623978435628,"gmtModify":1634024897560,"author":{"id":"3581763489080929","authorId":"3581763489080929","name":"Miao94","avatar":"https://static.tigerbbs.com/34f3df2688773fe9bc20c385589224ea","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581763489080929","authorIdStr":"3581763489080929"},"themes":[],"htmlText":"Comment&nbsp;","listText":"Comment&nbsp;","text":"Comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/168519834","repostId":"1197275653","repostType":4,"repost":{"id":"1197275653","kind":"news","pubTimestamp":1623976968,"share":"https://www.laohu8.com/m/news/1197275653?lang=&edition=full","pubTime":"2021-06-18 08:42","market":"us","language":"en","title":"Downtrodden Okta Stock Still Has a Chance to Shine Again","url":"https://stock-news.laohu8.com/highlight/detail?id=1197275653","media":"InvestorPlace","summary":"OKTA stock is a well-positioned player in the increasingly hot cybersecurity space\nIn May 2021, mult","content":"<p>OKTA stock is a well-positioned player in the increasingly hot cybersecurity space</p>\n<p>In May 2021, multiple accounts associated with hacking group DarkSide received $4.4 million worth of ransom in&nbsp;<b>Bitcoin</b>(CCC:<b><u>BTC-USD</u></b>) after a cyberattack on the Colonial Pipeline. The impact of this attack led to a significant increase in gas prices. It also left some stations on the East Coast empty for a period. Ultimately, this event thrust&nbsp;cybersecurity stocks&nbsp;like<b>&nbsp;Okta</b>(NASDAQ:<b><u>OKTA</u></b>) stock back into the spotlight.</p>\n<p>You might be quick to add OKTA stock to your list of cybersecurity companies to buy after this attack. After all, it’s a company that specializes in identity security. However, the bullish case doesn’t come without some challenges.</p>\n<p>So, here’s a closer look at whether Okta is worth buying in 2021.</p>\n<p><b>OKTA Stock Has Ongoing Advantages</b></p>\n<p>While some investing trends come and go (just take a look at the whacky ridememe stockshave been going on), one thing is guaranteed moving forward. Cybersecurity — and the companies that specialize in the space — will&nbsp;remain&nbsp;<i>invaluable</i>.</p>\n<p>In our increasingly hyper-connected world, the need for digital security services has no end. When it comes to Okta’s offerings in this space, it provides&nbsp;high-quality security solutions&nbsp;to identity protection.</p>\n<p>Breaking it down a bit further, the company offers a&nbsp;cloud-based security system&nbsp;that’s capable of intertwining with on-site applications. It’s designed to support modern work-based ecosystems that frequently rely on a combination of multiple cloud applications, user devices like laptops and phones, as well as external users’ (customers or business partners) systems and&nbsp;own custom apps.</p>\n<p>The more “inhabitants” in the ecosystem, the greater the number of security risks it carries (and the more complex it becomes for IT teams to handle). So, rather than require multiple logins for each element and user, Okta links them through a single sign-on using its secure process. Okta also allows you to combine multi-factor authentication functionality with its customizable “Universal Directory.” Essentially, this helps IT teams determine the level of access per user within the entire system.</p>\n<p>That’s a super fancy way of saying Okta’s services are a strong solution to your modern IT team’s day-to-day problems. According to the company, it enables companies to “[overcome] the economic and technological limitations of any legacy identity management scheme […] [they] are currently using.”</p>\n<p>This is all highly relevant to the investment thesis behind OKTA stock. After all, its unique security solution is the lifeblood of the company’s future. And that future is bright.</p>\n<p>With the onset of an increasingly remote workforce upon us, alongside the arrival of a“Cyber Pandemic,”— both of which were byproducts of the social impact of Covid-19 — IT solutions should remain hot commodities long-term. Consider the following:</p>\n<ul>\n <li>“The percentage of workers permanently working from home is&nbsp;expected to doublein 2021.”</li>\n <li>“Worldwide cybercrime costs will hit&nbsp;$6 trillion annually by 2021.”</li>\n <li>“Security services accounted for an estimated 50% of cybersecurity budgets in 2020.”</li>\n <li>Looking at the frequency of ransomware attacks alone, the rate has increased from one every 40 seconds in 2016 to an attack&nbsp;every 11 seconds in 2021.</li>\n</ul>\n<p>Clearly, companies are now willing to fork out the dough to stay safe. And the need for this safety is only growing. All of this should keep Okta in business for years to come. It should also help drive OKTA stock over a longer-term time frame.</p>\n<p>But, as with most investment cases, things aren’t&nbsp;<i>that</i>&nbsp;simple.</p>\n<p><b>The Downsides with Okta</b></p>\n<p>While OKTA stock had a strong run in 2020 (a 115% increase), it’s down about 10% so far in 2021. Much of that could be attributed to the pandemic catalyst tapering off. However, slowing revenue growth is another likely cause.</p>\n<p>Last year, Okta experienced massive 40% growth. The company now&nbsp;projects 30% revenue growth&nbsp;for next year. As<i>The Motley Fool’s</i>&nbsp;Travis Hoium&nbsp;explains, “with&nbsp;growth stocks, any reduction in the expected growth rate of the company can cause shares to plummet.”</p>\n<p>The difference between 30% and 40% growth might not seem significant to some. However, several analysts issued price-target downgrades on the news earlier this year. Piper Sandler issued a cut to $235 from their $250 price target (a 6% reduction). Likewise, BMO Capital Markets changed its target from $285 to $265 (a 7% reduction).</p>\n<p>The reduced growth projections (alongside dwindling post-pandemic hype) is a large reason for Okta’s pain in 2021. But there are also valuation concerns to contend with. At the start of the year, tech stocks suffered a selloff. Much of that’s due to inflated valuations within the space and continuing&nbsp;concerns that we’re in a tech bubble.</p>\n<p>Whether or not you agree with that broader market assessment, many argue that the valuation for OKTA stock is&nbsp;pricey relative to its peers. Plus, this concern gains further traction when you consider the following: “More than 70 percent&nbsp;of security executives believe that their budgets for fiscal year 2021 will shrink.” If these executives are correct, that could intensify the prospective reduction in Okta’s growth.</p>\n<p><b>Is OKTA Stock an Ugly Buy?</b></p>\n<p>That certainly puts a dent in the bullish case for OKTA stock. But I don’t think it should be taken as a sign of complete doom.</p>\n<p>When it comes to Okta, there’s nothing exceptionally<i>ugly</i>about the company. However, the valuation and growth concerns are legitimate, depending on what you expect from the stock. As such, there are at least two core questions to ask yourself moving forward:</p>\n<ul>\n <li><b>Do you expect Okta to continue growing near the 40% rate it enjoyed last year?</b>Okta projects a 10% reduction in growth and this coincides with the anticipated reduction in security budgets for 2021 (70%-plus of executives expect this to happen). If you’re looking for Okta to keep growing at a higher rate, then it might be time to walk away.</li>\n <li><b>Do you believe in Okta’s long-term viability?</b>As mentioned earlier, the world is only getting more remote and IT security systems are only getting more intricate and necessary. Okta is a key player in this space and its services are generally well-regarded. If it continues to produce high-quality solutions, the company should have a strong foundation for continued growth (albeit at a less impressive rate).</li>\n</ul>\n<p>Ultimately, when it comes to OKTA stock, I don’t think there’s reason to drop it. Unless, of course, you’re seeking more impressive growth narratives. Moving forward, longer-term investors ought to pay close attention to its continued viability to compete successfully in the cybersecurity space.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Downtrodden Okta Stock Still Has a Chance to Shine Again</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDowntrodden Okta Stock Still Has a Chance to Shine Again\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-18 08:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/downtrodden-okta-stock-still-has-chance-to-shine-again/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>OKTA stock is a well-positioned player in the increasingly hot cybersecurity space\nIn May 2021, multiple accounts associated with hacking group DarkSide received $4.4 million worth of ransom in ...</p>\n\n<a href=\"https://investorplace.com/2021/06/downtrodden-okta-stock-still-has-chance-to-shine-again/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OKTA":"Okta Inc."},"source_url":"https://investorplace.com/2021/06/downtrodden-okta-stock-still-has-chance-to-shine-again/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197275653","content_text":"OKTA stock is a well-positioned player in the increasingly hot cybersecurity space\nIn May 2021, multiple accounts associated with hacking group DarkSide received $4.4 million worth of ransom in Bitcoin(CCC:BTC-USD) after a cyberattack on the Colonial Pipeline. The impact of this attack led to a significant increase in gas prices. It also left some stations on the East Coast empty for a period. Ultimately, this event thrust cybersecurity stocks like Okta(NASDAQ:OKTA) stock back into the spotlight.\nYou might be quick to add OKTA stock to your list of cybersecurity companies to buy after this attack. After all, it’s a company that specializes in identity security. However, the bullish case doesn’t come without some challenges.\nSo, here’s a closer look at whether Okta is worth buying in 2021.\nOKTA Stock Has Ongoing Advantages\nWhile some investing trends come and go (just take a look at the whacky ridememe stockshave been going on), one thing is guaranteed moving forward. Cybersecurity — and the companies that specialize in the space — will remain invaluable.\nIn our increasingly hyper-connected world, the need for digital security services has no end. When it comes to Okta’s offerings in this space, it provides high-quality security solutions to identity protection.\nBreaking it down a bit further, the company offers a cloud-based security system that’s capable of intertwining with on-site applications. It’s designed to support modern work-based ecosystems that frequently rely on a combination of multiple cloud applications, user devices like laptops and phones, as well as external users’ (customers or business partners) systems and own custom apps.\nThe more “inhabitants” in the ecosystem, the greater the number of security risks it carries (and the more complex it becomes for IT teams to handle). So, rather than require multiple logins for each element and user, Okta links them through a single sign-on using its secure process. Okta also allows you to combine multi-factor authentication functionality with its customizable “Universal Directory.” Essentially, this helps IT teams determine the level of access per user within the entire system.\nThat’s a super fancy way of saying Okta’s services are a strong solution to your modern IT team’s day-to-day problems. According to the company, it enables companies to “[overcome] the economic and technological limitations of any legacy identity management scheme […] [they] are currently using.”\nThis is all highly relevant to the investment thesis behind OKTA stock. After all, its unique security solution is the lifeblood of the company’s future. And that future is bright.\nWith the onset of an increasingly remote workforce upon us, alongside the arrival of a“Cyber Pandemic,”— both of which were byproducts of the social impact of Covid-19 — IT solutions should remain hot commodities long-term. Consider the following:\n\n“The percentage of workers permanently working from home is expected to doublein 2021.”\n“Worldwide cybercrime costs will hit $6 trillion annually by 2021.”\n“Security services accounted for an estimated 50% of cybersecurity budgets in 2020.”\nLooking at the frequency of ransomware attacks alone, the rate has increased from one every 40 seconds in 2016 to an attack every 11 seconds in 2021.\n\nClearly, companies are now willing to fork out the dough to stay safe. And the need for this safety is only growing. All of this should keep Okta in business for years to come. It should also help drive OKTA stock over a longer-term time frame.\nBut, as with most investment cases, things aren’t that simple.\nThe Downsides with Okta\nWhile OKTA stock had a strong run in 2020 (a 115% increase), it’s down about 10% so far in 2021. Much of that could be attributed to the pandemic catalyst tapering off. However, slowing revenue growth is another likely cause.\nLast year, Okta experienced massive 40% growth. The company now projects 30% revenue growth for next year. AsThe Motley Fool’s Travis Hoium explains, “with growth stocks, any reduction in the expected growth rate of the company can cause shares to plummet.”\nThe difference between 30% and 40% growth might not seem significant to some. However, several analysts issued price-target downgrades on the news earlier this year. Piper Sandler issued a cut to $235 from their $250 price target (a 6% reduction). Likewise, BMO Capital Markets changed its target from $285 to $265 (a 7% reduction).\nThe reduced growth projections (alongside dwindling post-pandemic hype) is a large reason for Okta’s pain in 2021. But there are also valuation concerns to contend with. At the start of the year, tech stocks suffered a selloff. Much of that’s due to inflated valuations within the space and continuing concerns that we’re in a tech bubble.\nWhether or not you agree with that broader market assessment, many argue that the valuation for OKTA stock is pricey relative to its peers. Plus, this concern gains further traction when you consider the following: “More than 70 percent of security executives believe that their budgets for fiscal year 2021 will shrink.” If these executives are correct, that could intensify the prospective reduction in Okta’s growth.\nIs OKTA Stock an Ugly Buy?\nThat certainly puts a dent in the bullish case for OKTA stock. But I don’t think it should be taken as a sign of complete doom.\nWhen it comes to Okta, there’s nothing exceptionallyuglyabout the company. However, the valuation and growth concerns are legitimate, depending on what you expect from the stock. As such, there are at least two core questions to ask yourself moving forward:\n\nDo you expect Okta to continue growing near the 40% rate it enjoyed last year?Okta projects a 10% reduction in growth and this coincides with the anticipated reduction in security budgets for 2021 (70%-plus of executives expect this to happen). If you’re looking for Okta to keep growing at a higher rate, then it might be time to walk away.\nDo you believe in Okta’s long-term viability?As mentioned earlier, the world is only getting more remote and IT security systems are only getting more intricate and necessary. Okta is a key player in this space and its services are generally well-regarded. If it continues to produce high-quality solutions, the company should have a strong foundation for continued growth (albeit at a less impressive rate).\n\nUltimately, when it comes to OKTA stock, I don’t think there’s reason to drop it. Unless, of course, you’re seeking more impressive growth narratives. Moving forward, longer-term investors ought to pay close attention to its continued viability to compete successfully in the cybersecurity space.","news_type":1},"isVote":1,"tweetType":1,"viewCount":245,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164049649,"gmtCreate":1624162617681,"gmtModify":1634009964297,"author":{"id":"3581763489080929","authorId":"3581763489080929","name":"Miao94","avatar":"https://static.tigerbbs.com/34f3df2688773fe9bc20c385589224ea","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581763489080929","authorIdStr":"3581763489080929"},"themes":[],"htmlText":"Great&nbsp;","listText":"Great&nbsp;","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/164049649","repostId":"1175119628","repostType":4,"isVote":1,"tweetType":1,"viewCount":760,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":168563539,"gmtCreate":1623978866321,"gmtModify":1634024876165,"author":{"id":"3581763489080929","authorId":"3581763489080929","name":"Miao94","avatar":"https://static.tigerbbs.com/34f3df2688773fe9bc20c385589224ea","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581763489080929","authorIdStr":"3581763489080929"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/168563539","repostId":"2144411077","repostType":4,"isVote":1,"tweetType":1,"viewCount":303,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":167827446,"gmtCreate":1624260901785,"gmtModify":1634008746465,"author":{"id":"3581763489080929","authorId":"3581763489080929","name":"Miao94","avatar":"https://static.tigerbbs.com/34f3df2688773fe9bc20c385589224ea","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581763489080929","authorIdStr":"3581763489080929"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/167827446","repostId":"2144870437","repostType":4,"isVote":1,"tweetType":1,"viewCount":486,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":167827619,"gmtCreate":1624260885531,"gmtModify":1634008746712,"author":{"id":"3581763489080929","authorId":"3581763489080929","name":"Miao94","avatar":"https://static.tigerbbs.com/34f3df2688773fe9bc20c385589224ea","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581763489080929","authorIdStr":"3581763489080929"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/167827619","repostId":"1111222251","repostType":4,"repost":{"id":"1111222251","kind":"news","pubTimestamp":1624259801,"share":"https://www.laohu8.com/m/news/1111222251?lang=&edition=full","pubTime":"2021-06-21 15:16","market":"us","language":"en","title":"30Y Treasury Yield Tumbles Below 2.00%, Japanese Stocks Plunge","url":"https://stock-news.laohu8.com/highlight/detail?id=1111222251","media":"zerohedge","summary":"Short-dated Treasury yields are extending their rise from Friday's bloodbath as the collapse of the ","content":"<p>Short-dated Treasury yields are extending their rise from Friday's bloodbath as the collapse of the long-end of the term structure accelerates in early Asia trading.</p>\n<p>2Y is back above the Fed Funds rate...</p>\n<p><img src=\"https://static.tigerbbs.com/8b00147e9ac51186c9910c1b0226d4a8\" tg-width=\"500\" tg-height=\"273\"><i>Source: Bloomberg</i></p>\n<p>and 30Y yields are back below 2.00%...</p>\n<p><img src=\"https://static.tigerbbs.com/f8f5270edd9cc600dfb21ceba4cf0e77\" tg-width=\"500\" tg-height=\"273\"></p>\n<p>... for the first time since March...</p>\n<p><img src=\"https://static.tigerbbs.com/57cd958ccfbd05605a1803b430baa2ee\" tg-width=\"500\" tg-height=\"273\"><i>Source: Bloomberg</i></p>\n<p>10Y yields are at their lowest since early March...</p>\n<p><img src=\"https://static.tigerbbs.com/63a614b415615f0cb00431f4491227a5\" tg-width=\"500\" tg-height=\"268\"><i>Source: Bloomberg</i></p>\n<p>And Japanese equity markets are none too happy with Powell's policy error malarkey...</p>\n<p><img src=\"https://static.tigerbbs.com/3de5627dd059fff0076ce68b72e2c7c9\" tg-width=\"500\" tg-height=\"271\"><i>Source: Bloomberg</i></p>\n<p>AsLance Roberts noted earlier,<b>there have been ZERO times in history when the Fed started a rate hiking campaign that did not lead to a negative outcome.</b>We suggest this time won’t be any different.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>30Y Treasury Yield Tumbles Below 2.00%, Japanese Stocks Plunge</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n30Y Treasury Yield Tumbles Below 2.00%, Japanese Stocks Plunge\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-21 15:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.zerohedge.com/markets/30y-treasury-yield-tumbles-below-200-japanese-stocks-plunge><strong>zerohedge</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Short-dated Treasury yields are extending their rise from Friday's bloodbath as the collapse of the long-end of the term structure accelerates in early Asia trading.\n2Y is back above the Fed Funds ...</p>\n\n<a href=\"https://www.zerohedge.com/markets/30y-treasury-yield-tumbles-below-200-japanese-stocks-plunge\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯","SPY":"标普500ETF",".SPX":"S&P 500 Index"},"source_url":"https://www.zerohedge.com/markets/30y-treasury-yield-tumbles-below-200-japanese-stocks-plunge","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111222251","content_text":"Short-dated Treasury yields are extending their rise from Friday's bloodbath as the collapse of the long-end of the term structure accelerates in early Asia trading.\n2Y is back above the Fed Funds rate...\nSource: Bloomberg\nand 30Y yields are back below 2.00%...\n\n... for the first time since March...\nSource: Bloomberg\n10Y yields are at their lowest since early March...\nSource: Bloomberg\nAnd Japanese equity markets are none too happy with Powell's policy error malarkey...\nSource: Bloomberg\nAsLance Roberts noted earlier,there have been ZERO times in history when the Fed started a rate hiking campaign that did not lead to a negative outcome.We suggest this time won’t be any different.","news_type":1},"isVote":1,"tweetType":1,"viewCount":752,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":167827959,"gmtCreate":1624260863571,"gmtModify":1634008747080,"author":{"id":"3581763489080929","authorId":"3581763489080929","name":"Miao94","avatar":"https://static.tigerbbs.com/34f3df2688773fe9bc20c385589224ea","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581763489080929","authorIdStr":"3581763489080929"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/167827959","repostId":"1154249454","repostType":4,"isVote":1,"tweetType":1,"viewCount":829,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164077801,"gmtCreate":1624163479303,"gmtModify":1634009948197,"author":{"id":"3581763489080929","authorId":"3581763489080929","name":"Miao94","avatar":"https://static.tigerbbs.com/34f3df2688773fe9bc20c385589224ea","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581763489080929","authorIdStr":"3581763489080929"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/164077801","repostId":"1192473918","repostType":4,"repost":{"id":"1192473918","kind":"news","pubTimestamp":1624029343,"share":"https://www.laohu8.com/m/news/1192473918?lang=&edition=full","pubTime":"2021-06-18 23:15","market":"us","language":"en","title":"PLTR Stock: The Palantir-FAA Deal News Should Have Investors Smiling Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1192473918","media":"investorplace","summary":"Palantir Technologies(NYSE:PLTR) stock is on the move Friday following news of a deal with the Feder","content":"<p><b>Palantir Technologies</b>(NYSE:<b><u>PLTR</u></b>) stock is on the move Friday following news of a deal with the Federal Aviation Administration (FAA).</p>\n<p>The goal of this deal is toassist the FAA in modernizing its ” objectives for aviation safety.”This will have Palantir Technologies providing the agency with a data analyzing tool to help with that effort.</p>\n<p>According to a news release, this will have Palantir Technologies monitoring various safety aspects for the FAA. That includes reintegrating the 737 MAX fleet back into service after it was suspended due to fatal crashes.</p>\n<p>Palantir Technologies’ deal with the FAA is set to last for one year. However, there’s also the option to extend it by up to two years. The agreement has a maximum value of $18.4 million.</p>\n<p>Akash Jain, president of Palantir USG, said the following about the agreement with the FAA that should have PLTR stock gaining today.</p>\n<blockquote>\n “We are proud to be partnering with the Federal Aviation Administration to support their critical safety mission.”\n</blockquote>\n<p>The fact that PLTR stock is actually moving lower today despite this news is strange. The company’s shares did start off rising in early morning trading, but quickly fell back down to yesterday’s close before dipping even lower.</p>\n<p>It’s also worth noting that trading volume isn’t taking off on news of the FAA deal, either. As of this writing, more than 20 million shares of PLTR stock had changed hands. That’s still well below the company’s daily average trading volume of 57.8 million shares.</p>\n<p>PLTR stock was down 1.1% as of Friday morning.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PLTR Stock: The Palantir-FAA Deal News Should Have Investors Smiling Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPLTR Stock: The Palantir-FAA Deal News Should Have Investors Smiling Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-18 23:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/pltr-stock-the-palantir-faa-deal-news-should-have-investors-smiling-today/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Palantir Technologies(NYSE:PLTR) stock is on the move Friday following news of a deal with the Federal Aviation Administration (FAA).\nThe goal of this deal is toassist the FAA in modernizing its ” ...</p>\n\n<a href=\"https://investorplace.com/2021/06/pltr-stock-the-palantir-faa-deal-news-should-have-investors-smiling-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://investorplace.com/2021/06/pltr-stock-the-palantir-faa-deal-news-should-have-investors-smiling-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1192473918","content_text":"Palantir Technologies(NYSE:PLTR) stock is on the move Friday following news of a deal with the Federal Aviation Administration (FAA).\nThe goal of this deal is toassist the FAA in modernizing its ” objectives for aviation safety.”This will have Palantir Technologies providing the agency with a data analyzing tool to help with that effort.\nAccording to a news release, this will have Palantir Technologies monitoring various safety aspects for the FAA. That includes reintegrating the 737 MAX fleet back into service after it was suspended due to fatal crashes.\nPalantir Technologies’ deal with the FAA is set to last for one year. However, there’s also the option to extend it by up to two years. The agreement has a maximum value of $18.4 million.\nAkash Jain, president of Palantir USG, said the following about the agreement with the FAA that should have PLTR stock gaining today.\n\n “We are proud to be partnering with the Federal Aviation Administration to support their critical safety mission.”\n\nThe fact that PLTR stock is actually moving lower today despite this news is strange. The company’s shares did start off rising in early morning trading, but quickly fell back down to yesterday’s close before dipping even lower.\nIt’s also worth noting that trading volume isn’t taking off on news of the FAA deal, either. As of this writing, more than 20 million shares of PLTR stock had changed hands. That’s still well below the company’s daily average trading volume of 57.8 million shares.\nPLTR stock was down 1.1% as of Friday morning.","news_type":1},"isVote":1,"tweetType":1,"viewCount":654,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164057829,"gmtCreate":1624162517661,"gmtModify":1634009965847,"author":{"id":"3581763489080929","authorId":"3581763489080929","name":"Miao94","avatar":"https://static.tigerbbs.com/34f3df2688773fe9bc20c385589224ea","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581763489080929","authorIdStr":"3581763489080929"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/164057829","repostId":"1103331073","repostType":4,"isVote":1,"tweetType":1,"viewCount":819,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":165112950,"gmtCreate":1624105392170,"gmtModify":1634010651824,"author":{"id":"3581763489080929","authorId":"3581763489080929","name":"Miao94","avatar":"https://static.tigerbbs.com/34f3df2688773fe9bc20c385589224ea","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581763489080929","authorIdStr":"3581763489080929"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/165112950","repostId":"2144775875","repostType":4,"isVote":1,"tweetType":1,"viewCount":822,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166554781,"gmtCreate":1624019545543,"gmtModify":1634024045441,"author":{"id":"3581763489080929","authorId":"3581763489080929","name":"Miao94","avatar":"https://static.tigerbbs.com/34f3df2688773fe9bc20c385589224ea","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581763489080929","authorIdStr":"3581763489080929"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/166554781","repostId":"1158784745","repostType":4,"repost":{"id":"1158784745","kind":"news","pubTimestamp":1624017454,"share":"https://www.laohu8.com/m/news/1158784745?lang=&edition=full","pubTime":"2021-06-18 19:57","market":"sh","language":"en","title":"Inflation breakout will drive 10-year Treasury yields above 2% in coming months, Wells Fargo predicts","url":"https://stock-news.laohu8.com/highlight/detail?id=1158784745","media":"cnbc","summary":"Treasury yields may be about to break out.\nEven though yields temporarily fell after this week's Fed","content":"<div>\n<p>Treasury yields may be about to break out.\nEven though yields temporarily fell after this week's Federal Reserve decision on interest rates, Wells Fargo Securities' Michael Schumacher expects the ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/18/inflation-breakout-will-soon-drive-10-year-yields-above-2percent-wells-fargo.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inflation breakout will drive 10-year Treasury yields above 2% in coming months, Wells Fargo predicts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInflation breakout will drive 10-year Treasury yields above 2% in coming months, Wells Fargo predicts\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-18 19:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/18/inflation-breakout-will-soon-drive-10-year-yields-above-2percent-wells-fargo.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Treasury yields may be about to break out.\nEven though yields temporarily fell after this week's Federal Reserve decision on interest rates, Wells Fargo Securities' Michael Schumacher expects the ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/18/inflation-breakout-will-soon-drive-10-year-yields-above-2percent-wells-fargo.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index"},"source_url":"https://www.cnbc.com/2021/06/18/inflation-breakout-will-soon-drive-10-year-yields-above-2percent-wells-fargo.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1158784745","content_text":"Treasury yields may be about to break out.\nEven though yields temporarily fell after this week's Federal Reserve decision on interest rates, Wells Fargo Securities' Michael Schumacher expects the benchmark 10-year Treasury Note rate to end the year as high as 2.20%.\n\"The 10-year yield is going up a fair bit through the remainder of the year,\" the firm's head of macro strategy told CNBC's \"Trading Nation\" on Thursday. \"Not a steady rise to be sure. But we do think there's a pretty strong bear case to be made over the next six [to] seven months.\"\nSchumacherattributes the inflation comeback for his forecast— with an emphasis on the next 12 months.\n\"Core PCEwhich the Fed likes to look at is above 3% for the next year. It's an amazing number. We have not seen inflation like that in the U.S. on a sustained basis for a very long time,\" he said. \"This really gets at what the people in the market are focused on: Just how long is that inflation spike going to last? Is it transient? Is it transitory? I don't know. But it's troubling, that's pretty clear.\"\nIn his post-Fed decision research note, Schumacher said the Fed is still coming to terms with the inflation spike. According to Schumacher, the biggest risk facing the bond market and economy is the Fed's potential response to the strong economic comeback. If the Fed gets spooked, it would likely hike rates next year instead of waiting until at least 2023.\nSo far, Schumacher's bond market outlook is on target.\nComing into 2021, Schumacher predicted the10-year yieldwould hit 1.15% to 1.35% by this year's halfway point — with the caveat it could reach as high as 1.50%. He made the forecast when the yield was below 1% and months before the Covid-19 vaccines were widely available.\nOn Thursday, the 10-year yield closed at 1.51%. It's up almost 4% over the past week, but down 8% over the past three months.\nHe also doubts the dollar, which initially surged on a more hawkish Fed, will continue to extend its gains.\n\"For the first quarter of this year, the U.S. and arguably the U.K. had a tremendous advantage over most of the Western world in terms of Covid vaccinations. Now, a lot of countries are catching up, and you could view that as a proxy for future economic activity,\" Schumacher said. \"Thedollaris losing some of those tailwinds.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":627,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":168569542,"gmtCreate":1623978843086,"gmtModify":1634024877216,"author":{"id":"3581763489080929","authorId":"3581763489080929","name":"Miao94","avatar":"https://static.tigerbbs.com/34f3df2688773fe9bc20c385589224ea","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581763489080929","authorIdStr":"3581763489080929"},"themes":[],"htmlText":"Go go go","listText":"Go go go","text":"Go go go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/168569542","repostId":"1140460323","repostType":4,"isVote":1,"tweetType":1,"viewCount":205,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":168560878,"gmtCreate":1623978813294,"gmtModify":1634024878653,"author":{"id":"3581763489080929","authorId":"3581763489080929","name":"Miao94","avatar":"https://static.tigerbbs.com/34f3df2688773fe9bc20c385589224ea","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581763489080929","authorIdStr":"3581763489080929"},"themes":[],"htmlText":"Sad","listText":"Sad","text":"Sad","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/168560878","repostId":"2144744636","repostType":4,"repost":{"id":"2144744636","kind":"news","pubTimestamp":1623940250,"share":"https://www.laohu8.com/m/news/2144744636?lang=&edition=full","pubTime":"2021-06-17 22:30","market":"sg","language":"en","title":"Low dosage may be behind low efficacy of CureVac vaccine: Study leader","url":"https://stock-news.laohu8.com/highlight/detail?id=2144744636","media":"The Straits Times","summary":"BERLIN (REUTERS) - The low dosage might be a key reason why CureVac's Covid-19 vaccine reported disa","content":"<div>\n<p>BERLIN (REUTERS) - The low dosage might be a key reason why CureVac's Covid-19 vaccine reported disappointing efficacy in a pivotal late-stage trial, the scientist leading the study of the shot said ...</p>\n\n<a href=\"http://www.straitstimes.com/world/europe/low-dosage-may-be-behind-low-efficacy-of-curevac-vaccine-study-leader\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Low dosage may be behind low efficacy of CureVac vaccine: Study leader</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLow dosage may be behind low efficacy of CureVac vaccine: Study leader\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 22:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/world/europe/low-dosage-may-be-behind-low-efficacy-of-curevac-vaccine-study-leader><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BERLIN (REUTERS) - The low dosage might be a key reason why CureVac's Covid-19 vaccine reported disappointing efficacy in a pivotal late-stage trial, the scientist leading the study of the shot said ...</p>\n\n<a href=\"http://www.straitstimes.com/world/europe/low-dosage-may-be-behind-low-efficacy-of-curevac-vaccine-study-leader\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"http://www.straitstimes.com/world/europe/low-dosage-may-be-behind-low-efficacy-of-curevac-vaccine-study-leader","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2144744636","content_text":"BERLIN (REUTERS) - The low dosage might be a key reason why CureVac's Covid-19 vaccine reported disappointing efficacy in a pivotal late-stage trial, the scientist leading the study of the shot said on Thursday (June 17).\nThe German biotech's vaccine proved only 47 per cent effective in an initial trial, far lower than those of rivals BioNTech/Pfizer and Moderna, which are also based on mRNA technology and had efficacy rates well above 90 per cent.\nDr Peter Kremsner from the University Hospital in Tuebingen which is running the trial, told Reuters the low efficacy is \"very likely due to the dose\".\nUnlike BioNTech and Moderna, CureVac did not modify the mRNA used in the shots and therefore a higher dosage was not possible because of the side effects to be expected, Dr Kremsner said.\nWith just 12 micrograms of mRNA per dose, the company has been seeking to position itself as a low-dose alternative to BioNTech and Moderna's established shots with 30 and 100 micrograms per shot, respectively.\nIt is also easy to store and cheaper than the other mRNA shots too.\nThe European Union has agreed to pay 12 euros (S$19.20) per dose for supplies of the shot, an EU internal document shows, but has paid more than 15 euros for the other mRNA shots.\nHowever, the interim trial analysis goes some way to challenging the expectation, which was previously reflected in the company's share price, that all mRNA vaccines are similar.\nThe news wiped as much as 52 per cent off the company's value on Thursday.\nCureVac said on Wednesday that new variants had proved a headwind, but data from BioNTech and Moderna have, however, so far suggested only somewhat weaker protection against new variants.\nDr Kremsner said he thought it was probably a \"long shot\" as to whether CureVac's vaccine might turn out to be more effective when targeting a particular variant.\nThe disappointing results are a blow since European governments had been hoping to add it to their arsenal after age limits were imposed on the use of the Johnson & Johnson and AstraZeneca vaccines due to a link to extremely rare but potentially fatal clotting disorders.","news_type":1},"isVote":1,"tweetType":1,"viewCount":142,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":168587018,"gmtCreate":1623978789034,"gmtModify":1634024880334,"author":{"id":"3581763489080929","authorId":"3581763489080929","name":"Miao94","avatar":"https://static.tigerbbs.com/34f3df2688773fe9bc20c385589224ea","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581763489080929","authorIdStr":"3581763489080929"},"themes":[],"htmlText":"[微笑]&nbsp;","listText":"[微笑]&nbsp;","text":"[微笑]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/168587018","repostId":"2144690742","repostType":4,"repost":{"id":"2144690742","kind":"news","pubTimestamp":1623942044,"share":"https://www.laohu8.com/m/news/2144690742?lang=&edition=full","pubTime":"2021-06-17 23:00","market":"us","language":"en","title":"Column: The FDA's hasty approval of a new Alzheimer's drug is looking worse than ever","url":"https://stock-news.laohu8.com/highlight/detail?id=2144690742","media":"LA Times","summary":"The FDA's decision on Aduhelm sets up a healthcare spending crisis. \nFollowing a year in which the F","content":"<p><img src=\"https://static.tigerbbs.com/5a6526be3c93006ee9d37664f7f4650b\" tg-width=\"840\" tg-height=\"560\" referrerpolicy=\"no-referrer\">The FDA's decision on Aduhelm sets up a healthcare spending crisis.&nbsp;</p>\n<p>Following a year in which the Food and Drug Administration meekly allowed President Trump to denigrate its integrity and undermine its judgment, it wasn't clear that the agency could fall even lower in public and professional esteem.</p>\n<p>It's clear now. The FDA's widely criticized decision on June 7 to approve the new Alzheimer's drug Aduhelm despite a nearly complete absence of evidence that it works is looking worse and worse with every day that passes.</p>\n<p>The latest data point underscoring the disastrous consequences of the FDA approval is related to the sky-high average price of $56,000 a year for the drug set by its U.S. manufacturer, Biogen.</p>\n<blockquote>\n The limited evidence for the efficacy of Aduhelm raises the question of whether its large impact on health spending is justified.\n</blockquote>\n<p>Altarum consultants</p>\n<p>According to a report by the nonprofit healthcare consulting organization Altarum, if the drug is prescribed for only 1 million patients a year — the low end of Biogen's marketing expectations — by the mid-2020s it will account for more than 1% of all national health spending. In 2025, for instance, when total spending is expected to reach abut $5.3 trillion, $57 billion of that will be spent on Aduhelm.</p>\n<p>The drug will increase all prescription drug spending by 8% and non-retail drug spending — that is, for drugs that have to be administered in hospitals or doctors' offices — by 25%. If the patient caseload doubles, so will those figures. And the FDA's approval would allow Aduhelm to be prescribed for any of the nation's Alzheimer's patients, who currently number more than 6 million.</p>\n<p>That will impose higher costs on 56 million Americans enrolled in Medicare Part B even if they don't suffer from Alzheimer's, the Kaiser Family Foundation observes. That's because Medicare is required by law to cover all prescription medicines approved by the FDA. Part B premiums rise with Medicare's expenses, so the higher spending on Adulhelm will hit all premium payers in the pocketbook.</p>\n<p>If 1 million Part B members take Aduhelm, the program's 80% share of the drug's cost would come to nearly $45 billion, or well more than the $37 billion Medicare paid for all Part B drugs in 2019.</p>\n<p>Many Medicare patients taking the drug will be hard-pressed to afford it, KFF notes. Their 20%, uncapped share of Part B drug and services costs would mean an average bill of $11,200 per year for the drug. That's almost 40% of the $29,650 median income of Medicare Part B members.</p>\n<p>It gets worse. Altarum's estimates don't encompass the ancillary costs that will be associated with taking Aduhelm. Because the clinical trials revealed that about 30% of patients receiving a high dose of the drug experienced brain swelling, patients will have to undergo regular MRI tests to watch out for this dangerous side effect. They'll have to pay their share of that, too.</p>\n<p>This isn't the first time that a new drug has threatened to break the national healthcare bank. The best comparison may be the hepatitis-C drugs Sovaldi and Harvoni, which were priced by their developer, Gilead, at $84,000 and nearly $100,000 per year, respectively.</p>\n<p>Those drugs drove annual growth in retail prescription spending from 2.2% in 2013 to 13.5% in 2014, after their introduction, Altarum says.</p>\n<p>But there are differences. Sovaldi and Harvoni cured more than 90% of hepatitis-C patients after a single round of treatment, so the spending on any patient lasted less than a year; measuring their cost against the cost of treating hepatitis-C patients indefinitely made the cost-benefit balance obvious. Indeed, by 2016, when most patients had been treated, the prescription growth rate fell back to 1.7%,</p>\n<p>But Aduhelm is neither a cure nor a <a href=\"https://laohu8.com/S/AONE\">one</a>-time treatment. \"Aduhelm is to be administered repeatedly throughout the patient’s lifetime or until the patient and his or her physician elect to discontinue treatment,\" Altarum explains. \"The resultant growth in spending will therefore be sustained for the foreseeable future.\"</p>\n<p>The organization's bottom line: \"The limited evidence for the efficacy of Aduhelm raises the question of whether its large impact on health spending is justified.\"</p>\n<p>As bad as the FDA's decision is looking today, it didn't start out as a widely praised action, either. As we reported last week, <a href=\"https://laohu8.com/S/AONE.U\">one</a> member of the FDA scientific advisory committee that had examined results from the drug's clinical trials pronounced the action \"probably the worst drug approval decision in recent U.S. history” in a letter resigning from the committee.</p>\n<p>The 11-member committee had advised almost unanimously against the approval. <a href=\"https://laohu8.com/S/TWOA.U\">Two</a> other members also resigned after the FDA ignored the panel's recommendation.</p>\n<p>Alzheimer's specialists are concerned about the FDA decision for more than financial reasons. They fear that the existence of a drug with the FDA's imprimatur, as questionable as it is, will interfere with efforts to develop and test other treatments that may turn out to be more promising.</p>\n<p>Patients may be reluctant to enroll in trials of alternative drugs instead of taking Aduhelm, for example. And researchers trying to recruit trial subjects will have to reject anyone who has been treated with Aduhelm, because it will be difficult, if not impossible, to determine whether a given result is due to Aduhelm or the new drug.</p>\n<p>The longest-lasting effect, however, may be on the FDA's reputation for imposing rigorous safety and efficacy standards. The pharmaceutical industry has long groused about the agency's painstaking approval process, even though it has given the American drug market an image as the safest in the world.</p>\n<p>The drugmakers have consistently pushed for faster approvals and the acceptance of ever more sketchy evidence from clinical trials.</p>\n<p>Aaron S. Kesselheim, the Harvard professor who delivered that damning judgment about the FDA approval before resigning from its advisory panel, has called for the creation of a new agency to oversee drug approvals, presumably inoculated from pressure from Big Pharma.</p>\n<p>The FDA's approval of a high-priced, apparently low-value drug that will yield billions of dollars in profits for its manufacturer may even spur Congress finally to take America's drug-price crisis in hand and find a solution. That could be the silver lining around the cloud of the FDA's action.</p>\n<p>But it will be a shame that an agency that reigned as a bulwark against unsafe and ineffective drugs since its founding in 1906 had to fall so low to achieve that goal.</p>\n<p>This story originally appeared in Los Angeles Times.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Column: The FDA's hasty approval of a new Alzheimer's drug is looking worse than ever</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nColumn: The FDA's hasty approval of a new Alzheimer's drug is looking worse than ever\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 23:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/column-fdas-hasty-approval-alzheimers-144244083.html><strong>LA Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The FDA's decision on Aduhelm sets up a healthcare spending crisis. \nFollowing a year in which the Food and Drug Administration meekly allowed President Trump to denigrate its integrity and undermine ...</p>\n\n<a href=\"https://finance.yahoo.com/news/column-fdas-hasty-approval-alzheimers-144244083.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://finance.yahoo.com/news/column-fdas-hasty-approval-alzheimers-144244083.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2144690742","content_text":"The FDA's decision on Aduhelm sets up a healthcare spending crisis. \nFollowing a year in which the Food and Drug Administration meekly allowed President Trump to denigrate its integrity and undermine its judgment, it wasn't clear that the agency could fall even lower in public and professional esteem.\nIt's clear now. The FDA's widely criticized decision on June 7 to approve the new Alzheimer's drug Aduhelm despite a nearly complete absence of evidence that it works is looking worse and worse with every day that passes.\nThe latest data point underscoring the disastrous consequences of the FDA approval is related to the sky-high average price of $56,000 a year for the drug set by its U.S. manufacturer, Biogen.\n\n The limited evidence for the efficacy of Aduhelm raises the question of whether its large impact on health spending is justified.\n\nAltarum consultants\nAccording to a report by the nonprofit healthcare consulting organization Altarum, if the drug is prescribed for only 1 million patients a year — the low end of Biogen's marketing expectations — by the mid-2020s it will account for more than 1% of all national health spending. In 2025, for instance, when total spending is expected to reach abut $5.3 trillion, $57 billion of that will be spent on Aduhelm.\nThe drug will increase all prescription drug spending by 8% and non-retail drug spending — that is, for drugs that have to be administered in hospitals or doctors' offices — by 25%. If the patient caseload doubles, so will those figures. And the FDA's approval would allow Aduhelm to be prescribed for any of the nation's Alzheimer's patients, who currently number more than 6 million.\nThat will impose higher costs on 56 million Americans enrolled in Medicare Part B even if they don't suffer from Alzheimer's, the Kaiser Family Foundation observes. That's because Medicare is required by law to cover all prescription medicines approved by the FDA. Part B premiums rise with Medicare's expenses, so the higher spending on Adulhelm will hit all premium payers in the pocketbook.\nIf 1 million Part B members take Aduhelm, the program's 80% share of the drug's cost would come to nearly $45 billion, or well more than the $37 billion Medicare paid for all Part B drugs in 2019.\nMany Medicare patients taking the drug will be hard-pressed to afford it, KFF notes. Their 20%, uncapped share of Part B drug and services costs would mean an average bill of $11,200 per year for the drug. That's almost 40% of the $29,650 median income of Medicare Part B members.\nIt gets worse. Altarum's estimates don't encompass the ancillary costs that will be associated with taking Aduhelm. Because the clinical trials revealed that about 30% of patients receiving a high dose of the drug experienced brain swelling, patients will have to undergo regular MRI tests to watch out for this dangerous side effect. They'll have to pay their share of that, too.\nThis isn't the first time that a new drug has threatened to break the national healthcare bank. The best comparison may be the hepatitis-C drugs Sovaldi and Harvoni, which were priced by their developer, Gilead, at $84,000 and nearly $100,000 per year, respectively.\nThose drugs drove annual growth in retail prescription spending from 2.2% in 2013 to 13.5% in 2014, after their introduction, Altarum says.\nBut there are differences. Sovaldi and Harvoni cured more than 90% of hepatitis-C patients after a single round of treatment, so the spending on any patient lasted less than a year; measuring their cost against the cost of treating hepatitis-C patients indefinitely made the cost-benefit balance obvious. Indeed, by 2016, when most patients had been treated, the prescription growth rate fell back to 1.7%,\nBut Aduhelm is neither a cure nor a one-time treatment. \"Aduhelm is to be administered repeatedly throughout the patient’s lifetime or until the patient and his or her physician elect to discontinue treatment,\" Altarum explains. \"The resultant growth in spending will therefore be sustained for the foreseeable future.\"\nThe organization's bottom line: \"The limited evidence for the efficacy of Aduhelm raises the question of whether its large impact on health spending is justified.\"\nAs bad as the FDA's decision is looking today, it didn't start out as a widely praised action, either. As we reported last week, one member of the FDA scientific advisory committee that had examined results from the drug's clinical trials pronounced the action \"probably the worst drug approval decision in recent U.S. history” in a letter resigning from the committee.\nThe 11-member committee had advised almost unanimously against the approval. Two other members also resigned after the FDA ignored the panel's recommendation.\nAlzheimer's specialists are concerned about the FDA decision for more than financial reasons. They fear that the existence of a drug with the FDA's imprimatur, as questionable as it is, will interfere with efforts to develop and test other treatments that may turn out to be more promising.\nPatients may be reluctant to enroll in trials of alternative drugs instead of taking Aduhelm, for example. And researchers trying to recruit trial subjects will have to reject anyone who has been treated with Aduhelm, because it will be difficult, if not impossible, to determine whether a given result is due to Aduhelm or the new drug.\nThe longest-lasting effect, however, may be on the FDA's reputation for imposing rigorous safety and efficacy standards. The pharmaceutical industry has long groused about the agency's painstaking approval process, even though it has given the American drug market an image as the safest in the world.\nThe drugmakers have consistently pushed for faster approvals and the acceptance of ever more sketchy evidence from clinical trials.\nAaron S. Kesselheim, the Harvard professor who delivered that damning judgment about the FDA approval before resigning from its advisory panel, has called for the creation of a new agency to oversee drug approvals, presumably inoculated from pressure from Big Pharma.\nThe FDA's approval of a high-priced, apparently low-value drug that will yield billions of dollars in profits for its manufacturer may even spur Congress finally to take America's drug-price crisis in hand and find a solution. That could be the silver lining around the cloud of the FDA's action.\nBut it will be a shame that an agency that reigned as a bulwark against unsafe and ineffective drugs since its founding in 1906 had to fall so low to achieve that goal.\nThis story originally appeared in Los Angeles Times.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1028,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":168583238,"gmtCreate":1623978685324,"gmtModify":1634024886525,"author":{"id":"3581763489080929","authorId":"3581763489080929","name":"Miao94","avatar":"https://static.tigerbbs.com/34f3df2688773fe9bc20c385589224ea","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581763489080929","authorIdStr":"3581763489080929"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/168583238","repostId":"2144742686","repostType":4,"isVote":1,"tweetType":1,"viewCount":178,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":168589416,"gmtCreate":1623978669035,"gmtModify":1634024887332,"author":{"id":"3581763489080929","authorId":"3581763489080929","name":"Miao94","avatar":"https://static.tigerbbs.com/34f3df2688773fe9bc20c385589224ea","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581763489080929","authorIdStr":"3581763489080929"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/168589416","repostId":"2144742686","repostType":4,"isVote":1,"tweetType":1,"viewCount":498,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":168516150,"gmtCreate":1623978518070,"gmtModify":1634024893887,"author":{"id":"3581763489080929","authorId":"3581763489080929","name":"Miao94","avatar":"https://static.tigerbbs.com/34f3df2688773fe9bc20c385589224ea","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581763489080929","authorIdStr":"3581763489080929"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/168516150","repostId":"2144286417","repostType":4,"isVote":1,"tweetType":1,"viewCount":275,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":168513377,"gmtCreate":1623978452899,"gmtModify":1634024896749,"author":{"id":"3581763489080929","authorId":"3581763489080929","name":"Miao94","avatar":"https://static.tigerbbs.com/34f3df2688773fe9bc20c385589224ea","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581763489080929","authorIdStr":"3581763489080929"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/168513377","repostId":"1140460323","repostType":4,"isVote":1,"tweetType":1,"viewCount":248,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}